Novavax Inc. closed 61.59% short of its 52-week high of $17.81, which the company achieved on July 26th.

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

Key Points Canopy Growth seems unable to overcome the industrywide challenges it faces.Novavax's recent quarterly update, though strong, says little about its prospects. 10 stocks we like better than ...

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...

Novavax Inc. (NASDAQ:NVAX) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 17, Citi initiated ...

In this article, we will look at the 13 Cheap Healthcare Stocks with Huge Upside Potential. On July 8, Kate Moore, Citi Wealth CIO, appeared on CNBC’s ‘Squawk Box’ to talk about the recent rally in ...

Novavax Inc. closed 60.47% below its 52-week high of $17.81, which the company achieved on July 26th.

Major health groups sue HHS and Robert F. Kennedy Jr. over COVID-19 vaccine policy changes for children and pregnant ...

The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move ...

Novavax (NVAX) closed the most recent trading day at $6.61, moving -2.79% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.79% for the day. At the ...

Novavax Inc. research and ratings by Barron's. View NVAX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.